Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 8/20 | 1.00 |
| ▸ | MERTK | Q12866 | 13/20 | 0.87 |
| ▸ | AXL | P30530 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL29526181 | 0.96 | TYRO3 (0.93) | TYRO3MERTKAXL | |
| SCHEMBL19398176 | 0.93 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL23965835 | 0.93 | TYRO3 (0.87) | TYRO3MERTK | |
| SCHEMBL24371883 | 0.92 | TYRO3 (0.85) | TYRO3MERTKAXL | |
| SCHEMBL19398177 | 0.92 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398128 | 0.92 | TYRO3 (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398182 | 0.91 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398178 | 0.91 | MERTK (0.83) | TYRO3MERTKAXL | |
| SCHEMBL19377724 | 0.89 | TYRO3 (1.00) | TYRO3MERTKAXL | |
| SCHEMBL30367450 | 0.89 | TYRO3 (0.81) | TYRO3MERTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3813800-B1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORP (US) | 2025-05-07 | — | — | EP | claimed |
| CN-117771250-A | Formulations of AXL/MER inhibitors | 因赛特公司 | 2024-03-29 | — | — | CN | claimed |
| CN-113164398-B | Formulations of AXL/MER inhibitors | 因赛特公司 | 2023-11-03 | — | — | CN | claimed |
| US-11241438-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORPORATION | 2024-12-26 | — | — | US | disclosed |
| CN-117771250-A | Formulations of AXL/MER inhibitors | 因赛特公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113164398-B | Formulations of AXL/MER inhibitors | 因赛特公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3988552-A1 | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS | Incyte Corporation (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11241438-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3687996-B1 | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS | INCYTE CORP (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190112313-A1 | SALTS OF TAM INHIBITORS | WILMINGTON PHARMATECH | 2019-04-18 | — | — | US | disclosed |
| WO-2019067594-A1 | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241438-B2 | Formulations of an AXL/MER inhibitor | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
| US-20190112313-A1 | SALTS OF TAM INHIBITORS | PI4KA, PI4KB, PIK3CA | TYRO3 5/4885MERTK 38/4885AXL 4/4885 |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885MERTK 1/4885AXL 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.